Cargando…
Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches
The constant changes in cancer cell bioenergetics are widely known as metabolic reprogramming. Reprogramming is a process mediated by multiple factors, including oncogenes, growth factors, hypoxia-induced factors, and the loss of suppressor gene function, which support malignant transformation and t...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227908/ https://www.ncbi.nlm.nih.gov/pubmed/35745875 http://dx.doi.org/10.3390/pharmaceutics14061303 |
_version_ | 1784734301781229568 |
---|---|
author | Navarro, Carla Ortega, Ángel Santeliz, Raquel Garrido, Bermary Chacín, Maricarmen Galban, Néstor Vera, Ivana De Sanctis, Juan Bautista Bermúdez, Valmore |
author_facet | Navarro, Carla Ortega, Ángel Santeliz, Raquel Garrido, Bermary Chacín, Maricarmen Galban, Néstor Vera, Ivana De Sanctis, Juan Bautista Bermúdez, Valmore |
author_sort | Navarro, Carla |
collection | PubMed |
description | The constant changes in cancer cell bioenergetics are widely known as metabolic reprogramming. Reprogramming is a process mediated by multiple factors, including oncogenes, growth factors, hypoxia-induced factors, and the loss of suppressor gene function, which support malignant transformation and tumor development in addition to cell heterogeneity. Consequently, this hallmark promotes resistance to conventional anti-tumor therapies by adapting to the drastic changes in the nutrient microenvironment that these therapies entail. Therefore, it represents a revolutionary landscape during cancer progression that could be useful for developing new and improved therapeutic strategies targeting alterations in cancer cell metabolism, such as the deregulated mTOR and PI3K pathways. Understanding the complex interactions of the underlying mechanisms of metabolic reprogramming during cancer initiation and progression is an active study field. Recently, novel approaches are being used to effectively battle and eliminate malignant cells. These include biguanides, mTOR inhibitors, glutaminase inhibition, and ion channels as drug targets. This review aims to provide a general overview of metabolic reprogramming, summarise recent progress in this field, and emphasize its use as an effective therapeutic target against cancer. |
format | Online Article Text |
id | pubmed-9227908 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92279082022-06-25 Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches Navarro, Carla Ortega, Ángel Santeliz, Raquel Garrido, Bermary Chacín, Maricarmen Galban, Néstor Vera, Ivana De Sanctis, Juan Bautista Bermúdez, Valmore Pharmaceutics Review The constant changes in cancer cell bioenergetics are widely known as metabolic reprogramming. Reprogramming is a process mediated by multiple factors, including oncogenes, growth factors, hypoxia-induced factors, and the loss of suppressor gene function, which support malignant transformation and tumor development in addition to cell heterogeneity. Consequently, this hallmark promotes resistance to conventional anti-tumor therapies by adapting to the drastic changes in the nutrient microenvironment that these therapies entail. Therefore, it represents a revolutionary landscape during cancer progression that could be useful for developing new and improved therapeutic strategies targeting alterations in cancer cell metabolism, such as the deregulated mTOR and PI3K pathways. Understanding the complex interactions of the underlying mechanisms of metabolic reprogramming during cancer initiation and progression is an active study field. Recently, novel approaches are being used to effectively battle and eliminate malignant cells. These include biguanides, mTOR inhibitors, glutaminase inhibition, and ion channels as drug targets. This review aims to provide a general overview of metabolic reprogramming, summarise recent progress in this field, and emphasize its use as an effective therapeutic target against cancer. MDPI 2022-06-19 /pmc/articles/PMC9227908/ /pubmed/35745875 http://dx.doi.org/10.3390/pharmaceutics14061303 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Navarro, Carla Ortega, Ángel Santeliz, Raquel Garrido, Bermary Chacín, Maricarmen Galban, Néstor Vera, Ivana De Sanctis, Juan Bautista Bermúdez, Valmore Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches |
title | Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches |
title_full | Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches |
title_fullStr | Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches |
title_full_unstemmed | Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches |
title_short | Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches |
title_sort | metabolic reprogramming in cancer cells: emerging molecular mechanisms and novel therapeutic approaches |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227908/ https://www.ncbi.nlm.nih.gov/pubmed/35745875 http://dx.doi.org/10.3390/pharmaceutics14061303 |
work_keys_str_mv | AT navarrocarla metabolicreprogrammingincancercellsemergingmolecularmechanismsandnoveltherapeuticapproaches AT ortegaangel metabolicreprogrammingincancercellsemergingmolecularmechanismsandnoveltherapeuticapproaches AT santelizraquel metabolicreprogrammingincancercellsemergingmolecularmechanismsandnoveltherapeuticapproaches AT garridobermary metabolicreprogrammingincancercellsemergingmolecularmechanismsandnoveltherapeuticapproaches AT chacinmaricarmen metabolicreprogrammingincancercellsemergingmolecularmechanismsandnoveltherapeuticapproaches AT galbannestor metabolicreprogrammingincancercellsemergingmolecularmechanismsandnoveltherapeuticapproaches AT veraivana metabolicreprogrammingincancercellsemergingmolecularmechanismsandnoveltherapeuticapproaches AT desanctisjuanbautista metabolicreprogrammingincancercellsemergingmolecularmechanismsandnoveltherapeuticapproaches AT bermudezvalmore metabolicreprogrammingincancercellsemergingmolecularmechanismsandnoveltherapeuticapproaches |